Pfizer infuses $200M into CStone, scoring a second PD-L1 and outlining a sprawling China pact
Pfizer has engineered a wide-ranging China pact with CStone, with an initial $200 million investment and a license to the late-stage PD-L1 drug to get …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.